VK-II-86 is a non-β-blocking carvedilol analog. It prevents ouabain-Induced cardiotoxicity

VK-II-86 are effective to prevent ouabain-induced apoptosis and spontaneous contractions indicative of arrhythmogenic activity without affecting inotropy and demonstrated to be effective in human models, thus emerging as a therapeutic tool for the prevention of digitalis-induced arrhythmias and cardiac toxicity[1].